Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.

Cardio-Oncology
Lisa M KoppChildren’s Oncology Group

Abstract

Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. We evaluated children with osteosarcoma (OS) on two Children's Oncology Group trials with higher dose doxorubicin (375-600 mg/m2) preceded by dexrazoxane (10:1 dexrazoxane:doxorubicin dosing). They were evaluated after the minimum expected treatment time (METT), defined as 28 weeks. Cardiotoxicity was identified by echocardiography and serum N-terminal pro-brain natriuretic peptide (NT-proBNP). Second malignant neoplasm (SMN) data was collected. All children had normal left ventricular (LV) systolic function as measured by LV fractional shortening and no heart failure. The end-diastolic septal thickness Z-scores (P < 0.01) and LV mass Z-scores (P < 0.01) were significantly smaller than normal for body-surface area in both sexes. The average LV mass Z-scores were significantly smaller for girls (P < 0.01) and marginally smaller for boys (P = 0.06). Girls had significantly smaller LV end-diastolic dimension Z-scores normalized to BSA (P < 0.01) compared to healthy controls and had significant increases in NT-proBNP. Four children developed SM...Continue Reading

References

Mar 1, 1992·Journal of the American College of Cardiology·S D ColanS P Sanders
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Jan 1, 1993·Medical and Pediatric Oncology·J H SilberG Barber
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H WexlerM E Horowitz
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan S BielackKurt Winkler
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
Sep 19, 2002·Cancer·Deborah L Keefe
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E Lipshultz, Steven D Colan
Jul 13, 2004·The New England Journal of Medicine·Steven E LipshultzStephen E Sallan
Feb 18, 2005·The New England Journal of Medicine·Charlotte KragelundRolf Steffensen
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A MeyersHolcombe Grier
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron K TebbiCindy L Schwartz
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elly V BarryLewis B Silverman
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory T ArmstrongAnn C Mertens
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E Lipshultz, M Jacob Adams
Apr 26, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lynda M VroomanStephen E Sallan
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzStephen E Sallan
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Lorenzo MojaRoberto D'Amico
Mar 29, 2014·Pediatric Blood & Cancer·Alix E SeifRichard Aplenc
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J ChowSaro H Armenian
Jan 15, 2016·Cancer·Steven E LipshultzUNKNOWN Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium
Sep 7, 2016·British Journal of Clinical Pharmacology·Kelley K HutchinsSteven E Lipshultz
May 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jop C TeepenUNKNOWN DCOG LATER Study Group
Jul 7, 2017·Expert Opinion on Drug Metabolism & Toxicology·Neha BansalSteven E Lipshultz
Nov 1, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kelly D GetzRichard Aplenc

❮ Previous
Next ❯

Citations

Sep 24, 2020·International Journal of Molecular Sciences·Ingrid Lilienthal, Nikolas Herold
Nov 15, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joji IshidaJames Rutka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Elly V BarryLewis B Silverman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Eric J ChowSaro H Armenian
© 2021 Meta ULC. All rights reserved